Anavex reports publication of ANAVEX 3-71 in clinical journal

Anavex Life Sciences announced a peer-reviewed publication in Clinical Pharmacology in Drug Development, findings from the ANAVEX3-71 first-in-human study which achieved its cardiovascular safety objectives. The publication is entitled, ‘Concentration-QTc Relationship from a Single Ascending Dose Study of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for the Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer’s Disease’. The publication reports the cardiodynamic evaluation part of the single ascending dose study in healthy participants with the primary objective of assessing the effect of ANAVEX3-71 on ECG parameters.The results from this cardiodynamic evaluation demonstrated that ANAVEX3-71 at single ascending doses of 5 to 200 mg had no clinically relevant effects on any of the studied ECG parameters and hence confirmed the ANAVEX3-71 preclinical cardiovascular safety findings. These data also expand the safety objectives met in this first-in-human study of ANAVEX(R)3-71, further supporting its drug development program. “This published clinical study demonstrates Anavex’s commitment to advance Anavex’s clinical pipeline including ANAVEX3-71 for Schizophrenia, Frontotemporal Dementia, and Alzheimer’s Disease,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “We are looking forward to initiating the Phase 2 clinical trial in Schizophrenia with ANAVEX3-71 in the second half of 2023.”